Quantum BioPharma Licensee Unbuzzd Wellness Announces Investor Webinar for $5 Million Funding Round
Unbuzzd Wellness, a licensee of Quantum BioPharma, is hosting an investor webinar to raise up to $5 million for its scientifically proven alcohol metabolism beverage, representing a strategic non-dilutive funding opportunity for Quantum shareholders.
Quantum BioPharma Ltd. announced that its licensee, Unbuzzd Wellness Inc., will host an investor webinar on October 30, 2025, as part of its Regulation D 506(c) offering targeting up to $5 million in funding. The financing round is structured to avoid dilution to Quantum BioPharma shareholders, providing a strategic capital raise opportunity without affecting existing equity positions. The webinar will feature Unbuzzd's leadership team, including CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David, the former CEO of Celsius Holdings.
The event will focus on the investment opportunity surrounding unbuzzd(TM), a scientifically validated beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms. Company executives will discuss leadership strategy, distribution plans, and participate in a question-and-answer session with potential investors. The timing of this funding initiative comes as Quantum BioPharma maintains a 20.11% ownership stake in Unbuzzd Wellness as of March 31, 2025, according to the company's latest filings available at https://ibn.fm/yX7kt.
Quantum BioPharma's relationship with Unbuzzd Wellness includes significant financial arrangements that benefit the parent company. The licensing agreement guarantees Quantum BioPharma royalty payments of 7% of sales from unbuzzd(TM) until cumulative payments reach $250 million, after which the royalty decreases to 3% in perpetuity. This royalty structure provides Quantum BioPharma with long-term revenue potential from Unbuzzd's commercial success while retaining 100% rights to develop similar products for pharmaceutical and medical applications.
The announcement highlights Quantum BioPharma's broader corporate strategy of building a portfolio of innovative assets targeting neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation represents the underlying mechanism of multiple sclerosis, positioning Quantum BioPharma in the competitive neurodegenerative treatment space.
This funding initiative through Unbuzzd Wellness represents an important development in the alcohol-related health product market, where scientifically backed solutions for alcohol metabolism are gaining increased attention from both consumers and investors. The involvement of industry veterans, including former Celsius CEO Gerry David, adds credibility to Unbuzzd's commercial prospects and distribution capabilities. The non-dilutive nature of this funding round protects Quantum BioPharma shareholders while potentially generating significant future revenue through the royalty structure and maintained equity position in Unbuzzd Wellness.